Johnson & Johnson is hurdling past the asebestos scandal.
The company made headlines after receiving approval from the Food and Drug Administration.
The FDA approved Spravato as a fast-acting treatment for patients who have failed to find relief with at least two antidepressants, the Associated Press reported. The drug will cost between $590 and $885 depending on the dosage and before various insurance discounts and rebates.
Jim Cramer said that the suicide epidemic is a serious issue.
"Suicide is a terrible epidemic in this country," Cramer said. He continued to say that this is the first mental health drug in 40 years, so he expects a positive impact from the drug by next year.